---
title: 'Pfizer + ReViral, Novartis, Charles River + Explora Labs'
type: 'episode'
url: 'https://doc.social/episodes/pfizer-reviral-novartis-charles-river-explora-labs'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-04-13'
audio: 'unavailable — the host retired the file'
---

# Pfizer + ReViral, Novartis, Charles River + Explora Labs

Viral therapies, rare disease approvals, and lab space premiumsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesPfizer + ReViralNovartisCharles River + Explora LabsAbout the ShowLife Science Today is your source for storie…

## Summary

Viral therapies, rare disease approvals, and lab space premiums

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References
**[Pfizer + ReViral
](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-reviral-and-its-respiratory-syncytial-virus)[Novartis](https://www.hcp.novartis.com/products/vijoice/pik3ca-related-overgrowth-spectrum/efficacy/)
[Charles River + Explora Labs**
**](https://www.biospace.com/article/releases/charles-river-laboratories-acquires-explora-biolabs/?s=79)
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.